Optimisation of irinotecan dose in the treatment of patients with metastatic colorectal cancer after 5-FU failure: results from a multinational, randomised phase II study

Por Van Cutsem, E, Dirix, L, Van Laethem, J-L, Van Belle, S, Borner, M, Gonzalez Baron, M, Roth, A, Morant, R, Joosens, E, Gruia, G, Sibaud, D, Bleiberg, H
Publicado em 2005

A randomised phase II multicentre trial of irinotecan (CPT-11) using four different schedules in patients with metastatic colorectal cancer

Por Schoemaker, N E, Kuppens, I E L M, Moiseyenko, V, Glimelius, B, Kjaer, M, Starkhammer, H, Richel, D J, Smaaland, R, Bertelsen, K, Poulsen, J P, Voznyi, E, Norum, J, Fennelly, D, Tveit, K M, Garin, A, Gruia, G, Mourier, A, Sibaud, D, Lefebvre, P, Beijnen, J H, Schellens, J H M, ten Bokkel Huinink, W W
Publicado em 2004